Research & Development
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
12 September 2025 - Chinese biopharmaceutical company Shanghai Zhimeng Biopharma Inc announced on Thursday that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has...
EMA validates Daiichi Sankyo's ENHERTU type II variation application for HER2 positive metastatic solid tumours
11 September 2025 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) said on Thursday that the European Medicines Agency (EMA) has validated the Type II Variation marketing authorisation a...
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
11 September 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that it has received fast track designation from the US Food and Drug Administration (...
Implantica produces 10,000 RefluxStop units ahead of planned US launch
10 September 2025 - Medical technology company Implantica AG (Nasdaq First North Premier Growth Market: IMP A SDB) reported on Wednesday that it is ramping up production of its RefluxStop device with ...
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
10 September 2025 - Biopharmaceutical company Sobi (STO: SOBI) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for Nanoecapsulate...
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
9 September 2025 - Ionis Pharmaceuticals Inc (Nasdaq: IONS), a provider of RNA-targeted medicines, announced on Tuesday that the US Food and Drug Administration has granted Breakthrough Therapy design...